BioNTech says Sobi's Oelkers will replace Sahin as CEO

BNTX•2026-08-03

CEO succession announced

Aug. 3 (Reuters) - German biotech firm BioNTech said on Monday that Sobi's CEO Guido Oelkers will succeed Ugur Sahin as its chief executive.

Oelkers will take on the role from Feb. 1, 2027 at latest, the company said, after serving as CEO at the Stockholm-listed biopharmaceutical company since 2017.

Context on planned leadership changes

BioNTech announced in March its two co-founders and leading executives, Sahin and Chief Medical Officer Oezlem Tuereci, would leave the COVID-19 vaccine maker by the end of the year to start a new venture.

BioNTech says Sobi's Oelkers will replace Sahin as CEO

CEO succession announced

Context on planned leadership changes

Related News

Park Ha Biological prices US$ 1.8 million private placement at US$ 0.18 per share

Hancock Whitney Corporation <HWC.O>: Barclays raises target price to $82 from $80

T Rowe Price Group Inc <TROW.O>: Barclays Cuts Target Price to $103 From $108

Atmus Filtration Technologies Inc. <ATMU.N>: Wells Fargo cuts target price to $56 from $58

Solaris Energy Infrastructure, Inc. <SEI.N>: Wells Fargo Raises to Overweight From Equal Weight